<DOC>
	<DOCNO>NCT01854775</DOCNO>
	<brief_summary>There 2 cohort study , consist Part A Part B . The primary objective Cohort 1 evaluate steady state pharmacokinetics ( PK ) elvitegravir ( EVG ) tenofovir alafenamide ( TAF ) confirm dose elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( E/C/F/TAF ) single tablet regimen ( STR ) ( Part A ) evaluate safety tolerability E/C/F/TAF STR Week 24 ( Part B ) HIV-1 infect , antiretroviral ( ARV ) treatment-naive adolescent . The primary objective Cohort 2 evaluate PK EVG TAF virologically suppress HIV-1 infect child 6 &lt; 12 year age weigh ≥ 25 kg administer E/C/F/TAF STR ( Part A ) evaluate safety tolerability E/C/F/TAF STR Week 24 virologically suppress HIV-1 infected child 6 &lt; 12 year age weigh ≥ 25 kg .</brief_summary>
	<brief_title>Pharmacokinetics , Safety , Antiviral Activity Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide ( E/C/F/TAF ) Single Tablet Regimen ( STR ) HIV-1 Infected Antiretroviral Treatment-Naive Adolescents Virologically Suppressed Children</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Key Cohort 1 12 year &lt; 18 year age baseline Weight great equal 35 kg ( 77 lb ) Plasma HIV1 RNA level ≥ 1,000 copies/mL screening ( Roche COBAS TaqMan v2.0 ) Screening genotype report show sensitivity EVG , FTC tenofovir ( TFV ) No prior use approve experimental antiHIV1 drug length time Cohort 2 6 year &lt; 12 year age baseline Weight great equal 25 kg ( 55 lb ) Plasma HIV1 RNA &lt; 50 copies/mL ( undetectable HIV1 RNA level accord local assay use limit detection &gt; 50 copies/mL ) ≥ 180 consecutive day ( 6 month ) prior screen stable antiretroviral regimen , without documented history resistance component E/C/F/TAF STR . Key Hepatitis B hepatitis C virus infection Evidence active pulmonary extrapulmonary tuberculosis disease within 3 month screen visit . Individuals experience decompensated cirrhosis Pregnant lactating female Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Adolescents</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment-naive</keyword>
</DOC>